BioSpace News Archive

The reformulation of an existing generic drug could help neutralize the worse aspects of COVID

Specialty medical supply company SLI Medical announced the company has delivered more than 15,000 COVID-19 safety toolkits to JobsOhio to support small businesses in safely reopening during the pandemic.

BrickBio has made robust its novel site-specific conjugation process of inserting unnatural amino acids at any site within a protein or antibody

Bristol Myers Squibb announced that the company will take part in a fireside chat at Citi’s 15th Annual BioPharma Virtual Conference, which will be webcast on Tuesday, September 8, 2020.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced that management will participate in several upcoming investor conferences.

Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results

Rocket Pharmaceuticals, Inc. announces it has treated the first patient in the higher dose cohort in its open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector -based gene therapy for the treatment of Danon Disease.

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient.

Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced the appointments of Catherine Lee as senior vice president, general counsel and Theresa Lowry as vice president, human resources. “We are pleased to welcome Cathy and Theresa to the Metacrine team at this exciting time in the company’s evolution,” sai

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences. Citi’s 15 th Annual BioPharma Virtual Conference on September 9-10, 2020: 1 on 1 investor meetings. H.C. Wainwright 22nd Annual Global Investment Conference: presentation on September 14, 2020 at 12 p.m. ET (